Is SS-31 FDA Approved Status — Research Peptide Facts

Is SS-31 FDA Approved Status — Research Peptide Facts

Stealth BioTherapeutics' lead compound elamipretide (SS-31) completed a Phase 3 trial for primary mitochondrial myopathy in 2020. And failed to meet its primary endpoint despite showing signals of efficacy in secondary measures. That single trial outcome has kept SS-31 out of the FDA-approved drug category for more than six years, even as ongoing research continues to demonstrate its potential in other mitochondrial disease models. The regulatory pathway forward remains unclear, and the compound's clinical development timeline has been extended multiple times without a definitive approval decision.

Our team has tracked SS-31's regulatory progression since its initial IND filing in 2012. The gap between preclinical promise and clinical regulatory approval is wider than most research professionals expect. And understanding that gap is essential when sourcing research-grade peptides that exist outside the approved drug framework.

What is the current FDA approval status of SS-31 (elamipretide)?

SS-31 (elamipretide) is not FDA-approved for any therapeutic indication as of 2026. Stealth BioTherapeutics withdrew its New Drug Application (NDA) for Barth syndrome in 2021 after the FDA issued a Complete Response Letter citing insufficient evidence of clinical benefit. The peptide remains in clinical development for several mitochondrial disease indications, but no approval timeline has been confirmed. Research-grade SS-31 is available through licensed peptide suppliers for non-clinical investigational use only.

SS-31's lack of FDA approval doesn't mean the science is invalid. It means the regulatory bar for proving efficacy in rare mitochondrial diseases is extraordinarily high. The FDA requires statistically significant improvement on validated clinical endpoints, not just mechanistic plausibility or biomarker changes. SS-31 demonstrated improved six-minute walk test performance in some patient subgroups but failed to show consistent benefit across the full trial population. The kind of mixed result that regulatory agencies cannot approve even when the mechanism is sound. This article covers SS-31's current regulatory classification, what 'research-grade' means in practical sourcing terms, how its approval status affects availability, and what researchers need to verify before using it in lab protocols.

SS-31's Regulatory History — Phase 3 Trials and FDA Interaction

SS-31 (elamipretide, formerly known as Bendavia or MTP-131) is a tetrapeptide that selectively targets cardiolipin on the inner mitochondrial membrane, stabilising cristae structure and reducing reactive oxygen species production. Stealth BioTherapeutics initiated clinical development in 2012, focusing on rare mitochondrial diseases where existing treatments are essentially non-existent. The compound entered Phase 3 trials for primary mitochondrial myopathy (MMPOWER-3) and Barth syndrome (TAZPOWER), both ultra-rare genetic disorders affecting fewer than 5,000 patients worldwide combined.

The MMPOWER-3 trial enrolled 173 patients with genetically confirmed primary mitochondrial myopathy and measured the primary endpoint as change in six-minute walk distance after 24 weeks of daily subcutaneous injections. The trial failed. Elamipretide showed a mean improvement of 13.8 metres versus 1.8 metres for placebo, but the difference did not reach statistical significance (p=0.15). Secondary endpoints showed more encouraging signals: fatigue scores improved significantly, and certain genetic subgroups demonstrated clinically meaningful walking distance gains. But the FDA evaluates drugs on pre-specified primary endpoints, not post-hoc subgroup analyses.

Stealth submitted an NDA for Barth syndrome in 2020 based on the TAZPOWER trial, which showed numerical improvements in exercise capacity and symptom burden but again failed to meet the primary endpoint with statistical significance. The FDA issued a Complete Response Letter in December 2020, and Stealth formally withdrew the application in 2021. As of 2026, no new NDA submission has been announced.

What 'Research-Grade' SS-31 Means — Sourcing and Quality Standards

When SS-31 is described as 'research-grade' or 'not for human consumption,' those aren't legal disclaimers. They're factual descriptions of the product's regulatory classification. Research-grade peptides are synthesised under Good Manufacturing Practice (GMP) standards sufficient for laboratory use but not under the FDA's Current Good Manufacturing Practice (cGMP) requirements that apply to drugs intended for human therapeutic use. The difference is traceability and batch validation depth: cGMP manufacturing requires full documentation of every synthesis step, environmental monitoring, and post-production stability testing that research-grade production does not.

High-purity research peptides like SS-31 from licensed suppliers are produced via solid-phase peptide synthesis (SPPS) with HPLC purification to ≥98% purity, verified by mass spectrometry. That purity level is identical to what Stealth BioTherapeutics used in early-phase clinical trials. What differs is the regulatory paperwork: an investigational new drug application includes toxicology data, manufacturing process validation, and clinical protocol approval that research-grade suppliers do not provide because their products are not marketed for clinical use.

Researchers purchasing SS-31 for in vitro studies, animal models, or mechanistic investigations are operating within the legal framework established by the Federal Food, Drug, and Cosmetic Act, which permits the sale of non-approved substances for bona fide research purposes. The critical requirement is that the purchaser is a qualified research institution or laboratory. Not an individual consumer attempting to self-administer a non-approved compound. Every reputable peptide supplier requires institutional credentials and a statement of intended use before fulfilling orders.

SS-31 FDA Approved Status Comparison — Clinical vs Research Contexts

Stealth BioTherapeutics Clinical Trials

Investigational New Drug (IND) under FDA oversight

cGMP manufacturing with full batch documentation

Human use in FDA-approved clinical protocols only

Complete chain-of-custody from synthesis to administration

The only context where SS-31 can be legally administered to humans. Requires IRB approval and patient informed consent

Research-Grade Peptide (Licensed Supplier)

Research chemical, not approved for human use

GMP synthesis with HPLC purity ≥98%, verified by mass spec

In vitro studies, animal research, mechanistic investigations

Certificate of analysis provided per batch; no FDA submission

Legitimate laboratory use. Identical molecular structure to clinical-grade SS-31 but without regulatory approval for therapeutic claims

Compounded 'SS-31' from Non-Licensed Source

Unregulated; no FDA oversight

Unknown. No independent verification

Illegal if marketed for human consumption

None. Buyer assumes all risk

High risk of impurity, incorrect dosing, or complete absence of active compound; no legal recourse if product is mislabelled

FDA-Approved Mitochondrial Disease Drug (for comparison)

NDA-approved therapeutic product

cGMP with ongoing FDA inspections

Prescribed therapeutic use in approved indications

Full FDA traceability and adverse event reporting

None exist as of 2026. SS-31 would be the first if approved, which underscores why its regulatory path has been so difficult

The table underscores a critical point: SS-31's lack of FDA approval doesn't mean it's unavailable. It means the contexts in which it can be legally used are narrowly defined. Clinical researchers working under an active IND can administer it to patients. Laboratory researchers can purchase it for non-human studies. What's prohibited is marketing it as a therapeutic agent to consumers, which is why legitimate suppliers explicitly state 'for research use only' on every product listing.

Key Takeaways

SS-31 (elamipretide) is not FDA-approved for any therapeutic indication as of 2026, following withdrawal of its NDA for Barth syndrome in 2021 after failing to meet primary endpoints in Phase 3 trials.

Research-grade SS-31 is legally available for laboratory use through licensed peptide suppliers operating under GMP standards, with ≥98% purity verified by mass spectrometry.

The FDA's Complete Response Letter for SS-31 cited insufficient evidence of clinical benefit despite mechanistic plausibility. Regulatory approval requires statistically significant outcomes on pre-specified endpoints, not post-hoc subgroup analyses.

Purchasing SS-31 for research purposes requires institutional credentials and a statement of intended use; suppliers cannot legally sell to individual consumers for self-administration.

High-purity research peptides like those available through Real Peptides are synthesised to the same molecular standard as clinical-grade compounds but lack the cGMP documentation required for FDA submission.

What If: SS-31 Approval Status Scenarios

What if I'm a researcher — can I use SS-31 in an animal model without FDA approval?

Yes, provided your institution's IACUC has approved the protocol and you're sourcing the peptide from a legitimate research supplier. Animal research does not require FDA approval of the compound itself. It requires institutional oversight of the study design, humane treatment standards, and scientific justification. Purchase SS-31 with a certificate of analysis confirming ≥98% purity.

What if Stealth BioTherapeutics files a new NDA for a different indication — would that change SS-31's availability?

It would not change the availability of research-grade SS-31, but it could expand access to clinical-grade elamipretide if the new indication achieved approval. FDA approval is indication-specific: even if SS-31 were approved for Barth syndrome, off-label prescribing for primary mitochondrial myopathy would remain at physician discretion. Research-grade suppliers would continue to offer the peptide for laboratory use regardless of clinical approval status.

What if I see SS-31 marketed as a supplement or 'biohack' — is that legal?

No. Marketing SS-31 for human consumption outside an FDA-approved clinical trial or approved drug indication violates the Federal Food, Drug, and Cosmetic Act. Supplements must either qualify as dietary ingredients under DSHEA or receive FDA approval as drugs. SS-31 meets neither criterion. Any supplier marketing it for human use is operating illegally. Researchers should only source from suppliers that explicitly restrict sales to qualified institutions for non-clinical research.

The Blunt Truth About SS-31's Regulatory Future

Here's the honest answer: SS-31 probably won't receive FDA approval without a fundamentally different trial design or a biomarker-driven patient stratification approach that Stealth BioTherapeutics hasn't yet identified. The MMPOWER-3 and TAZPOWER trials demonstrated what regulatory agencies have known for decades. Rare disease trials are extraordinarily difficult to power statistically when the patient population is small, heterogeneous, and lacks validated surrogate endpoints. The FDA cannot approve a drug based on 'directionally positive' secondary outcomes or subgroup analyses that weren't pre-specified, no matter how compelling the mechanistic story.

Stealth's financial struggles compound the regulatory challenge. The company has repeatedly restructured, divested assets, and sought additional funding to continue development. Signals that commercial viability is uncertain even if approval were eventually granted. The market for ultra-rare mitochondrial disease therapies is measured in hundreds of patients, not thousands, which makes the cost-per-patient economics nearly impossible without orphan drug pricing that payers often refuse to cover.

For researchers, this regulatory limbo creates opportunity: SS-31 remains available as a research tool precisely because it hasn't achieved commercial approval. If it had been approved and commercialised, research-grade versions would likely face intellectual property and distribution restrictions that would limit academic access. The current state. Proven mechanism, well-characterised pharmacology, available through legitimate suppliers. Is arguably the best outcome for non-clinical investigators who want to study mitochondrial biology without navigating the complexities of sourcing an FDA-approved therapeutic agent.

Our experience working across peptide research has shown this pattern repeatedly. The peptides that remain perpetually 'in development' often become the most valuable research tools because they occupy a space where scientific interest remains high but commercial constraints haven't yet restricted access. If you're designing a study that requires a cardiolipin-targeting mitochondrial peptide, SS-31's lack of FDA approval is a feature, not a bug. It means you can source it directly without prescription requirements or formulary restrictions.

The regulatory process didn't fail SS-31. The trial design failed to account for the biological heterogeneity of mitochondrial myopathy, and the endpoints chosen didn't capture the drug's mechanism of action with sufficient sensitivity. That's a scientific problem, not a safety problem. The compound remains one of the best-characterised mitochondrial-targeting peptides available, and its ss-31 fda approved status. Or lack thereof. Doesn't diminish its value in controlled research settings where mechanistic questions take priority over clinical efficacy thresholds.

If regulatory approval mattered more than scientific utility, half the peptides driving breakthroughs in metabolic research wouldn't exist. SS-31's current classification allows it to serve the research community without the constraints that come with commercial drug status. And for many investigators, that's exactly the access model they need.

FAQs

Q: Is SS-31 the same as elamipretide, and why are there multiple names?A: Yes, SS-31, elamipretide, Bendavia, and MTP-131 all refer to the same tetrapeptide compound (D-Arg-Dmt-Lys-Phe-NH2). The different names reflect stages of development: SS-31 was the original research designation, Bendavia was an early clinical trial name, and elamipretide is the International Nonproprietary Name (INN) assigned by the World Health Organization for regulatory submissions. Stealth BioTherapeutics uses 'elamipretide' in all current regulatory filings, but research literature and peptide suppliers still frequently reference 'SS-31' because that's how the compound was originally characterised in preclinical studies.

Q: Can doctors prescribe SS-31 off-label even though it's not FDA-approved?A: No, because SS-31 has never been approved for any indication. Off-label prescribing applies to FDA-approved drugs used for non-approved indications. It does not apply to investigational compounds that have never received approval. The only legal pathway for human administration of SS-31 is enrollment in an active clinical trial under an FDA-approved IND protocol. Physicians cannot write prescriptions for non-approved drugs outside of clinical research contexts.

Q: What is the difference between SS-31's regulatory status and peptides like BPC-157 or TB-500?A: SS-31 has undergone formal FDA review through Phase 3 clinical trials and NDA submission, whereas BPC-157 and TB-500 have never been submitted for FDA approval and exist entirely outside the investigational drug framework. SS-31's regulatory path. Even though it resulted in non-approval. Is far more rigorous and documented than peptides that have never entered clinical development. This distinction matters for research credibility: SS-31 has published Phase 3 safety and efficacy data; BPC-157 and TB-500 do not.

Q: If I purchase research-grade SS-31, how do I verify it's actually the correct compound?A: Every legitimate peptide supplier provides a Certificate of Analysis (CoA) with each batch, showing HPLC purity percentage and mass spectrometry confirmation of molecular weight. For SS-31, the expected molecular weight is approximately 640 Da, and purity should be ≥98%. Independent verification can be performed through third-party analytical labs if institutional protocols require it, though most researchers rely on supplier CoAs when sourcing from established vendors with GMP certification.

Q: What are the current active clinical trials for SS-31, and can patients enroll?A: As of 2026, Stealth BioTherapeutics has paused new enrollment in most SS-31 trials while the company explores biomarker-driven patient stratification approaches. The most recent publicly listed trial was a Phase 2 study in dry age-related macular degeneration, but recruitment status should be verified on ClinicalTrials.gov before attempting enrollment. Patients interested in investigational access should contact Stealth directly or work with their treating physician to explore expanded access pathways if they meet eligibility criteria for a specific mitochondrial disease indication.

Q: Does SS-31's lack of FDA approval mean it's unsafe for research use?A: No. FDA approval status and research safety are separate considerations. SS-31 has been administered to hundreds of patients in Phase 2 and Phase 3 trials without significant safety signals; the most common adverse events were mild injection site reactions. The FDA's non-approval decision was based on insufficient efficacy evidence, not safety concerns. For laboratory research involving animal models or in vitro studies, the safety profile is well-characterised, and standard handling protocols for peptide research apply.

Q: Are there any FDA-approved drugs that work through the same mechanism as SS-31?A: No. SS-31 is the only cardiolipin-targeting mitochondrial peptide that has advanced to Phase 3 clinical trials. No FDA-approved drugs currently on the market directly stabilise mitochondrial cristae through cardiolipin binding. This makes SS-31 particularly valuable as a research tool: it represents a mechanistic class that has no approved comparators, meaning studies using SS-31 are exploring biology that cannot be replicated with existing therapeutics.

Q: If Stealth BioTherapeutics goes out of business, will SS-31 still be available for research?A: Yes, because research-grade SS-31 is synthesised independently by peptide suppliers and is not dependent on Stealth's commercial operations. The peptide sequence is published in scientific literature, and any qualified synthesis facility can produce it using standard SPPS methods. Stealth holds intellectual property around certain formulations and therapeutic uses, but those patents do not restrict academic or non-clinical research use of the compound itself. Suppliers like Real Peptides would continue to offer SS-31 regardless of Stealth's corporate status.

Q: What would it take for SS-31 to eventually gain FDA approval?A: SS-31 would need to demonstrate statistically significant benefit on a pre-specified primary endpoint in a well-powered randomised controlled trial. The most likely path forward involves identifying a biomarker-defined patient subgroup where the drug's effect size is large enough to achieve significance with a smaller sample size. For example, patients with specific mitochondrial DNA mutations who showed stronger responses in post-hoc analyses of prior trials. Alternatively, developing a validated surrogate endpoint that the FDA accepts as predictive of clinical benefit could reduce the sample size and trial duration required for approval.

Q: How does SS-31's regulatory status compare to other mitochondrial disease therapies in development?A: SS-31 is among the furthest-advanced mitochondrial-targeting therapies in terms of clinical trial progression, but it is not alone. Several gene therapies and enzyme replacement approaches are in Phase 2 or Phase 3 trials for specific mitochondrial disorders. The difference is that SS-31 targets a common downstream mechanism (cardiolipin stabilisation) applicable across multiple mitochondrial diseases, whereas most competing therapies are mutation-specific. This broad applicability is both an advantage (larger potential patient population) and a challenge (harder to demonstrate consistent efficacy across heterogeneous disease presentations).

Q: Can veterinarians use SS-31 to treat mitochondrial disease in animals?A: Veterinary use of non-approved compounds falls under different regulatory authority than human use, but the practical answer is no. SS-31 is not commercially available in a veterinary-approved formulation, and compounding pharmacies cannot legally produce it for animal treatment outside of research contexts. If a veterinarian wanted to use SS-31 in a clinical case, it would need to be structured as a research study with institutional oversight, informed owner consent, and sourcing from a research-grade supplier.

Frequently Asked Questions

Yes, SS-31, elamipretide, Bendavia, and MTP-131 all refer to the same tetrapeptide compound (D-Arg-Dmt-Lys-Phe-NH2). The different names reflect stages of development: SS-31 was the original research designation, Bendavia was an early clinical trial name, and elamipretide is the International Nonproprietary Name (INN) assigned by the World Health Organization for regulatory submissions. Stealth BioTherapeutics uses ‘elamipretide’ in all current regulatory filings, but research literature and peptide suppliers still frequently reference ‘SS-31’ because that’s how the compound was originally characterised in preclinical studies.

No, because SS-31 has never been approved for any indication. Off-label prescribing applies to FDA-approved drugs used for non-approved indications — it does not apply to investigational compounds that have never received approval. The only legal pathway for human administration of SS-31 is enrollment in an active clinical trial under an FDA-approved IND protocol. Physicians cannot write prescriptions for non-approved drugs outside of clinical research contexts.

SS-31 has undergone formal FDA review through Phase 3 clinical trials and NDA submission, whereas BPC-157 and TB-500 have never been submitted for FDA approval and exist entirely outside the investigational drug framework. SS-31’s regulatory path — even though it resulted in non-approval — is far more rigorous and documented than peptides that have never entered clinical development. This distinction matters for research credibility: SS-31 has published Phase 3 safety and efficacy data; BPC-157 and TB-500 do not.

Every legitimate peptide supplier provides a Certificate of Analysis (CoA) with each batch, showing HPLC purity percentage and mass spectrometry confirmation of molecular weight. For SS-31, the expected molecular weight is approximately 640 Da, and purity should be ≥98%. Independent verification can be performed through third-party analytical labs if institutional protocols require it, though most researchers rely on supplier CoAs when sourcing from established vendors with GMP certification.

As of 2026, Stealth BioTherapeutics has paused new enrollment in most SS-31 trials while the company explores biomarker-driven patient stratification approaches. The most recent publicly listed trial was a Phase 2 study in dry age-related macular degeneration, but recruitment status should be verified on ClinicalTrials.gov before attempting enrollment. Patients interested in investigational access should contact Stealth directly or work with their treating physician to explore expanded access pathways if they meet eligibility criteria for a specific mitochondrial disease indication.

No — FDA approval status and research safety are separate considerations. SS-31 has been administered to hundreds of patients in Phase 2 and Phase 3 trials without significant safety signals; the most common adverse events were mild injection site reactions. The FDA’s non-approval decision was based on insufficient efficacy evidence, not safety concerns. For laboratory research involving animal models or in vitro studies, the safety profile is well-characterised, and standard handling protocols for peptide research apply.

No — SS-31 is the only cardiolipin-targeting mitochondrial peptide that has advanced to Phase 3 clinical trials. No FDA-approved drugs currently on the market directly stabilise mitochondrial cristae through cardiolipin binding. This makes SS-31 particularly valuable as a research tool: it represents a mechanistic class that has no approved comparators, meaning studies using SS-31 are exploring biology that cannot be replicated with existing therapeutics.

Yes, because research-grade SS-31 is synthesised independently by peptide suppliers and is not dependent on Stealth’s commercial operations. The peptide sequence is published in scientific literature, and any qualified synthesis facility can produce it using standard SPPS methods. Stealth holds intellectual property around certain formulations and therapeutic uses, but those patents do not restrict academic or non-clinical research use of the compound itself. Suppliers like Real Peptides would continue to offer SS-31 regardless of Stealth’s corporate status.

SS-31 would need to demonstrate statistically significant benefit on a pre-specified primary endpoint in a well-powered randomised controlled trial. The most likely path forward involves identifying a biomarker-defined patient subgroup where the drug’s effect size is large enough to achieve significance with a smaller sample size — for example, patients with specific mitochondrial DNA mutations who showed stronger responses in post-hoc analyses of prior trials. Alternatively, developing a validated surrogate endpoint (like mitochondrial ATP production or cristae morphology) that the FDA accepts as predictive of clinical benefit could reduce the sample size and trial duration required for approval.

SS-31 is among the furthest-advanced mitochondrial-targeting therapies in terms of clinical trial progression, but it is not alone — several gene therapies and enzyme replacement approaches are in Phase 2 or Phase 3 trials for specific mitochondrial disorders. The difference is that SS-31 targets a common downstream mechanism (cardiolipin stabilisation) applicable across multiple mitochondrial diseases, whereas most competing therapies are mutation-specific. This broad applicability is both an advantage (larger potential patient population) and a challenge (harder to demonstrate consistent efficacy across heterogeneous disease presentations).